Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases
Akira Nishimura, Yuki Aoki, Yasuyoshi Ishiwata, Takuya Ichimura, Junichi Ueyama, Yuta Kawahara, Takahiro Tomoda, Maiko Inoue, Kazuaki Matsumoto, Kento Inoue, Haruka Hiroki, Shintaro Ono, Motoi Yamashita, Tsubasa Okano, Mari Tanaka‐Kubota, Miho Ashiarai, Satoshi Miyamoto, Reiji Miyawaki, Chika Yamagishi, Mari Tezuka, Teppei Okawa, Akihiro Hoshino, Akifumi Endo, Masato Yasuhara, Takahiro Kamiya, Noriko Mitsuiki, Toshiaki Ono, Takeshi Isoda, Masakatsu Yanagimachi, Daisuke Tomizawa, Masayuki Nagasawa, Shuki Mizutani, Michiko Kajiwara, Masatoshi Takagi, Hirokazu Kanegane, Kohsuke Imai, Tomohiro Morio
Topics & Concepts
FludarabineBusulfanMelphalanMedicineSevere combined immunodeficiencyTransplantationInternal medicinePrimary immunodeficiencyHematopoietic stem cell transplantationImmunodeficiencyTotal body irradiationGastroenterologyImmunologyCyclophosphamideOncologyChemotherapyImmune systemDiseaseBiologyGeneBiochemistryImmunodeficiency and Autoimmune DisordersHematopoietic Stem Cell TransplantationAutoimmune and Inflammatory Disorders Research